1.Retrospective Analysis of Stroke at Acute Stage Treated by Traditional Chinese Medicine Clinical Pathway
Jun Hao PENG ; Huai TU ; Jing Wen WANG ; Cai Ji LAI ; Hong Li PI ; Qiang SHEN ; Min Ya LIU ; Bing Zhi WU
Journal of Guangzhou University of Traditional Chinese Medicine 2017;34(6):805-809
Objective To evaluate the effect for stroke(cerebral infarction)at acute stage intervened by traditional Chinese medicine(TCM) clinical pathway. Methods A retrospective analysis was carried out in the patients before and after intervention by TCM clinical pathway during the year of 2013-2016. The outcomes included the entrance rate,completion percentage,aberration rate,severity,hospitalization time,and hospitalization fee as well as functional prognosis 30 d after discharge. Results A total of 792 cases was included,241 cases admitted in the year of 2013, 191 in the year of 2014, 135 in the year of 2015, and 225 in the year of 2016. In the year of 2014-2016,the entrance rate,completion percentage,hospitalization time,hospitalization fee,critical case percentage,and gender constituent ratio were steadily(P > 0.05). Modified Rankin Scale(mRS)for short-term functional prognosis mRS 0 ~ 2 percentage and aberration rate in the year of 2016 were superior to those in the year of 2014 and 2015(P < 0.05). Functional improvement on discharge day 30 in the year of 2014-2016 was superior to that in the year of 2013(P < 0.05). The hospitalization time and hospitalization fee in the year of 2014-2016 were a liffle higher than those in the year of 2013(P < 0.05), showing no obvious increase. Conclusion The application of TCM clinical pathway can make the diagnosis and treatment procedure of stroke at acute stage standardized,enhance the therapeutic effect,achieve or even exceed the goal of manage scheme.
2.Efficacy analysis of the acute endovascular treatment in patients with symptomatic severe anterior intracranial atherosclerotic stenosis
Haolin LIU ; Xiaoxin BAI ; Jun CAI ; Zhuli PENG ; Ruicong CHEN ; Shaoxue LI ; Huai TU ; Jiangling LIANG ; Yuejia LIN
Chinese Journal of Cerebrovascular Diseases 2024;21(3):175-183
Objective Observing the feasibility of acute endovascular treatment for patients with symptomatic anterior intracranial atherosclerotic severe stenosis.Method From Jun 2019 to Jun 2023,30 symptomatic anterior intracranial atherosclerotic severe stenosis cases were retrospectively collected in the Guangdong Hospital of Traditional Chinese Medicine to evaluate the risk stratification score and explore the safety and effectiveness of acute(≤72.0h)endovascular treatment.Endovascular treatment includes balloon dilation+self-expanding stent placement,balloon-mounted stent placement,and balloon dilation.From the clinical experience,the risk stratification score was based on the ABCD3-I score for transient ischemic attacks(TIA)and additional evaluation of cerebral watershed infarction to identify the risk of stroke progression or recurrence in acute stage of symptomatic intracranial artery stenosis.The score of 0-3 was defined as low-risk,4-7 as medium risk,and 8-13 as high-risk.The successful revascularization of blood flow is determined based on the residual stenosis≤50%and the extended thrombolysis in cerebral infarction(eTICI)>2c.The information of patient receiving endovascular treatment was recorded,including age,sex,risk factors of cerebrovascular disease(hypertension,diabetes,hyperlipidemia,hyperhomocysteinemia,drinking history,smoking history),onset data(time from onset to endovascular treatment,symptoms,progression),diseased vessels,risk stratification score,National Institutes of Health Stroke Scale(NIHSS)score before and 90 days after surgery,modified Rankin scale(mRS)score 90 days after surgery,intraoperative cerebrovascular events(intracranial hemorrhage,occlusion of responsible vessels),and postoperative cerebrovascular events 90 days after surgery(intracranial hemorrhage,cerebral infarction,TIA and in-stent restenosis)and deaths.Results Among 30 patients with symptomatic anterior intracranial atherosclerotic severe stenosis,3 patients were excluded from the time interval between onset and endovascular treatment>72.0 hours,1 patient needed long-term anticoagulant drugs due to other diseases,1 patient lost follow-up,3 patients coexisted with other cardiogenic cerebral embolism diseases,4 patients with non-atherosclerotic arterial stenosis,and 7 patients refused emergency endovascular treatment.11 patients were finally included.(1)All 11 patients were successfully treated with endovascular treatment,and 7 were males;age ranged from 52 to 76 years old,with a median age of 64 years old;there were 9 cases with hypertension,3 cases diabetes,7 cases hyperlipidemia,2 cases hyperhomocysteinemia(only 9cases performed the examination),2cases smoking history,1 case drinking history;time from onset to endovascular treatment is 4.0-72.0 h,with a median time of 12.0 h;there were 3 and 8 cases of infarction in the left and right hemispheres,respectively,with 4,3,and 2 cases accompanied with anterior-posterior watershed,medial watershed,and anlerior-medial-posterior watershed infarctions,and 1 case accompanied by posterior-medial,anterior-medial watershed infarctions.(2)Among the 1 1 patients,the risk stratification score was 10-13 points,with a median score of 11 points;preoperative NIHSS score ranged 0-11 points,with a median score of 7 points.(3)Among the 1 1 patients,10 lesions located in the middle cerebral artery and 1 in the C7 segment of the internal carotid artery;the preoperative stenosis rate was 70%to 99%,with a median stenosis rate of 86%;preoperative eTICI grading was 2a in 7 cases and 2b50 in 4 cases(with slow distal blood flow);9 cases received balloon dilation and self-expanding stent placement,1 case received balloon-mounted stent placement,and 1 case received balloon dilation treatment;the postoperative stenosis rate is 10%to 20%,with a median stenosis rate of 15%;there were 3 cases with postoperative eTICI grade 2c and 8 cases with grade 3.(4)Among the 11 patients,one experienced intracranial hemorrhage on the first day after surgery and one had a new cerebral infarction on the third day after surgery.Eight patients were followed up by imaging 90days after surgery,demonstrating 2 cases of in-stent restenosis;90 days post-surgery,NIHSS score was 0-20 points,with a median score of 2 points;after 90 days of surgery,the mRS score was 0-4 points,with a median score of 1 point.There were 8 patients with mRS score ≤ 2 and no death events occurred.Conclusions Preliminary analysis shows that acute endovascular treatment for symptomatic anterior intracranial atherosclerotic severe stenosis has certain effectiveness,but the safety needs to be further validated.The screening of high-risk patients using risk stratification scores still requires further exploration through large sample and multicenter studies.
3.Research Progress on TKI Resistance of CML Cells Mediated by MSC through CXCL12/CXCR4 Axis.
Li-Jun FANG ; Huai-Jun TU ; Jian LI
Journal of Experimental Hematology 2015;23(4):1221-1224
Although the tyrosinekinase inhibitors (TKI) displayed a significant curative effect on chronic myeloid leukemia (CML), but the drug resistance in treatment course of this disease still can not be avoided. Studies recently have shown that the mesenchymal stem cells (MSC) can induce CML cells to resist TKI therapy by CXCL12/CXCR4 axis from multiple aspects, such as the directional migration of CML cells, adherence to marrow cavity, the mediation of cell protective dormancy, activations of numerous survival signaling pathways, the suppression of mitochondrial-dependent apoptosis and the up-regulated expression of BCL-6. The combination of TKI and CXCR4 antagonists will be a novel treatment strategy to raise the genetic cure rate of CML. In this article, the pathways of drug resistance, pathways of sensitivity to CXCL12 and pathways of CML cell adherence to marrow cavity in CML cells mediated by MSC were reviewed.
Drug Resistance, Neoplasm
;
Humans
;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
;
Protein Kinase Inhibitors
;
Protein-Tyrosine Kinases
;
Signal Transduction
;
Stem Cells
4.Clinical features of preterm infants with a birth weight less than 1 500 g undergoing different intensities of resuscitation: a multicenter retrospective analysis.
Miao QIAN ; Zhang-Bin YU ; Xiao-Hui CHEN ; Yan XU ; Yue-Lan MA ; Shan-Yu JIANG ; Huai-Yan WANG ; Zeng-Qin WANG ; Liang-Rong HAN ; Shuang-Shuang LI ; Hong-Yan LU ; Jun WAN ; Yan GAO ; Xiao-Qing CHEN ; Li ZHAO ; Ming-Fu WU ; Hong-Juan ZHANG ; Mei XUE ; Ling-Ling ZHU ; Zhao-Fang TIAN ; Wen-Juan TU ; Xin-Ping WU ; Shu-Ping HAN ; Xiao-Qi GU
Chinese Journal of Contemporary Pediatrics 2021;23(6):593-598
OBJECTIVE:
To evaluate the clinical features of preterm infants with a birth weight less than 1 500 g undergoing different intensities of resuscitation.
METHODS:
A retrospective analysis was performed for the preterm infants with a birth weight less than 1 500 g and a gestational age less than 32 weeks who were treated in the neonatal intensive care unit of 20 hospitals in Jiangsu, China from January 2018 to December 2019. According to the intensity of resuscitation in the delivery room, the infants were divided into three groups:non-tracheal intubation (
RESULTS:
Compared with the non-tracheal intubation group, the tracheal intubation and ECPR groups had significantly lower rates of cesarean section and use of antenatal corticosteroid (
CONCLUSIONS
For preterm infants with a birth weight less than 1 500 g, the higher intensity of resuscitation in the delivery room is related to lower rate of antenatal corticosteroid therapy, lower gestational age, and lower birth weight. The infants undergoing tracheal intubation or ECRP in the delivery room have an increased incidence rate of adverse clinical outcomes. This suggests that it is important to improve the quality of perinatal management and delivery room resuscitation to improve the prognosis of the infants.
Birth Weight
;
Cesarean Section
;
China
;
Female
;
Gestational Age
;
Humans
;
Infant
;
Infant, Newborn
;
Infant, Premature
;
Pregnancy
;
Retrospective Studies
5.Guarantee of Quality and Clinical Efficacy of Chinese Materia Medica Preparation: Control of Quality Transfer Process of Chinese Materia Medica
Li-xia MA ; Huai-jin YANG ; Jia ZHANG ; Yi-ting YU ; Xin-ya ZHUANG ; Yue ZHOU ; Wei GU ; Chun-qin MAO ; Jun CHEN ; Tu-lin LU ; Guo-jun YAN
Chinese Journal of Experimental Traditional Medical Formulae 2021;27(14):222-228
Traditional Chinese medicine (TCM) is the treasure of the Chinese nation. As an important raw material for clinical treatment of diseases, Chinese materia medica plays an extremely important role. However, in the process of transformation from traditional wild collection of animals and plants to modern artificial cultivation and industrial production of preparations, whether the quality of Chinese materia medica is fully transferred will directly affect the quality and clinical efficacy of Chinese materia medica preparation. From the field to the sickbed, process control of quality transfer of Chinese materia medica is the key to guarantee quality and curative effect. In this paper, the whole process that affects the quality of Chinese materia medica preparations such as seed and seedling, planting and breeding, harvesting and processing, processing of decoction pieces and preparation production was analyzed. Paying attention to the whole process of quality control of Chinese materia medica is of great significance to improve the quality of Chinese materia medica preparations and promote the rapid development of TCM. Based on this, the author intended to analyze the key control links in the quality transfer process of Chinese materia medica (breeding, planting areas and field management, timely harvesting and intensive primary processing, appropriate processing, optimization of preparation technology, standardization of packaging and informationization of storage and transportation), in order to provide reference for the design and development of Chinese materia medica preparations guided by clinical value.